Nanoprobe enables measurement of proteins in living cells

Their results support the view that the generation of A-beta is among the first steps leading to the characteristic neurodegeneration of Alzheimer's disease.

"To study the dynamics of A-beta and tau, we needed a way to trigger the expression of both proteins and a tool to track dynamic changes of protein expression," says lead author Feng Liang, PhD, a research fellow at the Rowland Institute.

In 2008, some of the MGH members of the current team showed that the anesthetic isoflurane induced characteristic changes seen in Alzheimer's disease - including activation of cell-death enzymes and generation of A-beta - in cultured cells and in mouse brains.

In 2014, the Harvard/Rowland researchers demonstrated the ability of their nanodevice to detect levels of intracellular proteins in living, cultured cells.

The current study merges both of these accomplishments to investigate a key question regarding the mechanism of Alzheimer's disease - whether generation of A-beta precedes or follows the generation of the abnormal form of tau that characterises the disease.

The tip of the device developed by the Harvard/Rowland investigators is around 50 nm (billionths of a meter) across, about 200 times smaller than a single cell.

An integrated gold nanorod serves as the biosensor for what is called surface plasmon resonance - an oscillation of electrons in response to a light signal that can generate an optical readout reflecting protein binding signals. Antibodies targeting specific proteins can be integrated into the probe to give specific measurements of protein levels.

The team first demonstrated that it was possible to use the nanoplasmonic fiber tip probe (nFTP) to quantify protein levels in individual cells without affecting their vitality and viability.

Using the nFTP device the investigators then tracked the changing levels of A-beta and the Alzheimer's-associated form of tau, which is characterised by excess phosphate molecules, in cultured cells that had been treated with isoflurane.

The readings indicated that the increase in A-beta expression preceded the rise in phosphorylated tau levels by several hours. The team then showed that, while blocking A-beta expression reduced tau levels, blocking tau did not prevent the initial rise in A-beta.

However, without phosphorylated tau expression, A-beta levels eventually began to drop, suggesting a sequence in which A-beta generation stimulates tau phosphorylation, which promotes further generation of A-beta.

"We have brought the traditional immunoassay into living cells with exquisite sensitivity," says Qimin Quan, PhD, a junior fellow at the Rowland Institute and co-corresponding author of the Nano Letters report.

"The device is still limited in its ability to measure a large number of single cells, requiring further improvement. But its high-sensitivity, label-free and single-cell capability make it a unique tool for diagnosing clinically obtained limited samples."

Zhongcong Xie, MD, PhD, director of the Geriatric Anesthesia Research Unit in the MGH Department of Anesthesia, Critical Care and Pain Medicine and co-corresponding author of the study, adds, "Each year approximately 8.5 million patients with Alzheimer's disease need anesthesia and surgical care worldwide. Learning how anesthesia affects the mechanisms behind

Alzheimer's will require collaboration among specialists in anesthesia, neurology and engineering. Moreover, this use of both an anesthetic and the nFTP device to measure interactions between A-beta and tau is just a first step." Xie is a professor of Anesthesia at Harvard Medical School.